POZEN announces receipt of $20 million milestone payment from AstraZeneca
POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the US Food and Drug Administration approval of VIMOVOâ``¢ delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.
Chapel Hill drug company Pozen reported this morning that it posted a $13.3 million profit in the second-quarter -- reversing its loss of a year ago -- thanks to a $20 million milestone payment from partner GlaxoSmithKline.